BENZENO SHARON sold $3.5M of ADPT
BENZENO SHARON (Chief Commercial Ofc Imm Med) sold 165,802 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $21.13 ($21.00–$21.14, $3.50M total) across 2 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider activity but does not introduce new company-specific fundamentals or catalysts.
Market read
Traders may monitor insider activity, but this specific 10b5-1 sale is unlikely to drive a sustained repricing absent other news.
What to watch
Insider sales can be misread; without accompanying changes in guidance, trials, or financing, the trading signal is weak.
Background
The article is an SEC Form 4 insider transaction report for Adaptive Biotechnologies (ADPT).
Ticker impact
SEC Form 4 shows officer Benzeno Sharon sold 165,802 shares of Adaptive Biotechnologies (ADPT) for about $3.50M under a 10b5-1 plan.
Likely limited/short-lived impact; any move would be more sentiment-driven than fundamental.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and the article provides no new operational, regulatory, or financial catalyst.
Market effects
No sector read-through; this is company-specific insider liquidity disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider transaction; officer sale disclosed.
- insiderBenzeno Sharon
Chief Commercial Officer, Immune Med; reported open-market sale under a 10b5-1 plan.
